OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

1 Projects | 1 Researchers | $4,989,741 Invested

2024

Allyx Therapeutics

Timothy Siegert, PhD

Clinical Phase 2 Proof-of-Concept Study Evaluating the Effect of ALX-001 on Biomarkers of Synapse Structure and Function.

  • Funding Amount: $4,989,741
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Other
  • Status: Active